Interestingly, H19 expression levels in plasma discriminated PAH patients from controls, correlated with RV function and long-term survival rate, in two independent IPAH patient cohorts, which suggests that plasma H19 levels are promising biomarkers in RV failure and outcomes in PAH [111]. The gene discussed is H19; the disease is pulmonary arterial hypertension.